Healthy ParticipantsPhase 1NCT07588139
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
A Phase 1 study testing Povorcitinib and Ruxolitinib in people with Healthy Participants, run by Incyte Corporation at 1 site in United States.
Trial summary
The purpose of this study is to evaluate the interstitial concentrations using the open-flow microperfusion device and plasma pharmacokinetics following multiple doses of povorcitinib or topical ruxolitinib cream in healthy adult participants. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Participants
- What is being tested?
- Povorcitinib and Ruxolitinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteUnited States
- Study dates
- 18 May 2026to 5 Oct 2026
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Ability to comprehend and willingness to sign a written ICF for the study.
- Aged 18 to 65 years, inclusive, at the time of signing the ICF.
- Body mass index between 18.0 and 30.5 kg/m2, inclusive.
- No clinically significant findings on screening evaluations (clinical, laboratory, and ECG).
- Ability to swallow and retain oral medication.
- Willingness to avoid pregnancy or fathering children.
Who cannot join
- History of uncontrolled or unstable cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening.
- Participants with any history of an autoimmune disease diagnosis.
- History of cardiovascular, cerebrovascular, peripheral vascular, or thrombotic disease or uncontrolled hypertension.
- History or presence of an abnormal ECG.
- Presence or history of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn's disease or chronic pancreatitis).
- Any malignancies or history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ.
Show all 37Show fewer
- Current or recent (within 3 months of screening) clinically significant gastrointestinal disease or surgery (including cholecystectomy; excluding appendectomy and hernia repair) that could affect the absorption of study drug.
- Any major surgery within 4 weeks of screening.
- Donation of blood to a blood bank or participation in a clinical study (except a screening visit) within 4 weeks of screening (within 2 weeks for plasma-only donation).
- Blood transfusion within 4 months of check-in (Day -1).
- Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment (includes latent treated tuberculosis).
- Known tuberculosis infection that is active or participant-reported history of tuberculosis or treatment thereof.
- Positive test for HBV, HCV, or HIV. Participants whose results are compatible with prior immunization for or immunity due to infection with HBV may be included at the discretion of the investigator.
- Has received a live vaccine (including attenuated) or anticipation of need for such a vaccine during the study within 3 months prior to the first dose of study drug. Note: Examples of live vaccines include but are not limited to the following: measles, mumps, rubella, chickenpox/zoster, yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid. Seasonal influenza vaccines for injection are generally killed-virus vaccines and are allowed; however, intranasal influenza vaccines are live, attenuated vaccines and are not allowed.
- Medical or self-reported history of alcoholism within 3 months of screening.
- History of significant alcohol use within 3 months of screening, defined as regular alcohol consumption > 21 units per week for males and > 14 units for females (1 unit = 8 oz of beer or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type).
- Positive urine or breath test for ethanol or positive urine or serum screen for drugs of abuse that are not otherwise explained by permitted concomitant medications or diet.
- Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study treatment with another investigational medication or current enrollment in another investigational drug study.
- Current treatment or treatment within 15 days or 5 half-lives (whichever is longer) before the first dose/application of study treatment with strong inducers or strong and moderate inhibitors of CYP3A4, P-gp, or BCRP (refer to the Drug Interaction Database for prohibited drugs.
- Consumption of red wine, Seville oranges, grapefruit or grapefruit juice, pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices within 72 hours before the first dose of study drug.
- History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
- Known hypersensitivity or severe reaction to povorcitinib or any excipients of povorcitinib, to ruxolitinib or any excipients of ruxolitinib or any JAK inhibitors.
- Inability to undergo venipuncture or tolerate venous access.
- History of tobacco or nicotine containing product use within 1 month of screening.
- Use of prescription drugs (including hormonal contraceptives) within 14 days of study treatment administration/application or nonprescription medications/products (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days before study treatment administration/application. However, occasional and standard dose paracetamol, acetaminophen, ibuprofen, and standard dose vitamins are permitted. Mega dose vitamins or supplements are not permissible.
- Women who are pregnant or breastfeeding.
- Any condition that would interfere with full participation in the study, including administration/application of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
- Excessive exercise (ie Iron man®, triathlon, etc) within 7 days before check-in (Day -1).
- Tattoo or scarring at skin sample sites.
- Participants prone to keloid or hypertrophic scar formation or any known wound healing disorder.
- Not willing to avoid excessive sun exposure, steam baths, sauna, swimming, and other strenuous activities for 14 days after Day 12 to ensure good tissue regeneration.
- Pronounced hairiness on the planned application sites, dOFM probe insertion sites, and skin biopsy collection sites, that may negatively affect dose application, probe placement, and/or sample testing.
- Not willing to refrain from shaving the planned application sites, dOFM probe insertion sites, and skin biopsy collection sites, or using skin care products on the planned application sites, dOFM probe insertion sites, and skin biopsy collection sites, for at least 5 days before Day 1.
- Not willing to avoid sunbathing, using tanning salons, or using spray/lotion tanning agents within 7 days prior to Day 1 dose administration/application.
- Presence of needle phobia.
- Increased risk of thrombosis (eg, personal or first-degree relative[s] history of deep vein thrombosis).
- Other protocol-defined Inclusion/Exclusion Criteria may apply.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Open-Label, Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
The purpose of this study is to evaluate the interstitial concentrations using the open-flow microperfusion device and plasma pharmacokinetics following multiple doses of povorcitinib or topical ruxolitinib cream in healthy adult participants.
- Conditions
- Healthy Participants
- Being tested
- Povorcitinib, Ruxolitinib
- Keywords
- INCB054707
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PovorcitinibDrug
Also called INCB054707
Oral; Tablet
RuxolitinibDrug
Ruxolitinib cream applied topically.
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1: Ruxolitinib 1.5 % Cream | Experimental | Ruxolitinib cream applied topically twice daily. Receives: Drug: Ruxolitinib |
| Cohort 2: Povorcitinib | Experimental | Povorcitinib will be administered at the protocol defined dose. Receives: Drug: Povorcitinib |
| Cohort 3: Povorcitinib | Experimental | Povorcitinib will be administered at the protocol defined dose. Receives: Drug: Povorcitinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pharmacokinetics Parameter (PK): Cmax of dermal interstitial fluid (dISF) ruxolitinib
Defined as the maximum observed plasma concentration.
Measured: Up to Day 12
Pharmacokinetics Parameter: AUClast of dISF ruxolitinib
Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.
Measured: Up to Day 12
Pharmacokinetics Parameter: AUC∞ of dISF ruxolitinib
Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.
Measured: Up to Day 12
Pharmacokinetics Parameter: Cmax of dISF povorcitinib
Defined as the maximum observed plasma concentration.
Measured: Up to Day 12
Pharmacokinetics Parameter: AUClast of dISF povorcitinib
Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.
Measured: Up to Day 12
Pharmacokinetics Parameter: AUC∞ of dISF povorcitinib
Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.
Measured: Up to Day 12
Pharmacokinetics Parameter: Cmax of plasma ruxolitinib
Defined as the maximum observed plasma concentration.
Measured: Up to Day 12
Pharmacokinetics Parameter: AUClast of plasma ruxolitinib
Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.
Measured: Up to Day 12
Pharmacokinetics Parameter: AUC∞ of plasma ruxolitinib
Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.
Measured: Up to Day 12
Pharmacokinetics Parameter: Cmax of plasma povorcitinib
Defined as the maximum observed plasma concentration.
Measured: Up to Day 12
Pharmacokinetics Parameter: AUClast of plasma povorcitinib
Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.
Measured: Up to Day 12
Pharmacokinetics Parameter: AUC∞ of plasma povorcitinib
Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.
Measured: Up to Day 12
Secondary outcomes (21)
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Defined as any adverse event, either reported for the first time or the worsening of a pre-existing event, occurring after first dose of study treatment.
Measured: Up to Day 28
Pharmacokinetics Parameter: tmax of dISF ruxolitinib
Defined as the time to maximum concentration.
Measured: Up to Day 12
Pharmacokinetics Parameter: t½ of dISF ruxolitinib
Defined as the apparent terminal-phase disposition half-life.
Measured: Up to Day 12
Pharmacokinetics Parameter: CL/F of dISF ruxolitinib
Defined as the apparent clearance.
Measured: Up to Day 12
Pharmacokinetics Parameter: Vz/F of dISF ruxolitinib
Defined as the apparent volume of distribution.
Measured: Up to Day 12
Pharmacokinetics Parameter: λz of dISF ruxolitinib
Defined as the terminal-phase disposition rate constant.
Measured: Up to Day 12
Pharmacokinetics Parameter: tmax of dISF povorcitinib
Defined as the time to maximum concentration.
Measured: Up to Day 12
Pharmacokinetics Parameter: t½ of dISF povorcitinib
Defined as the apparent terminal-phase disposition half-life.
Measured: Up to Day 12
Pharmacokinetics Parameter: CL/F of dISF povorcitinib
Defined as the apparent clearance.
Measured: Up to Day 12
Pharmacokinetics Parameter: Vz/F of dISF povorcitinib
Defined as the apparent volume of distribution.
Measured: Up to Day 12
Pharmacokinetics Parameter: λz of dISF povorcitinib
Defined as the terminal-phase disposition rate constant.
Measured: Up to Day 12
Pharmacokinetics Parameter: tmax of plasma ruxolitinib
Defined as the time to maximum concentration.
Measured: Up to Day 12
Pharmacokinetics Parameter: t½ of plasma ruxolitinib
Defined as the apparent terminal-phase disposition half-life.
Measured: Up to Day 12
Pharmacokinetics Parameter: CL/F of plasma ruxolitinib
Defined as the apparent clearance.
Measured: Up to Day 12
Pharmacokinetics Parameter: Vz/F of plasma ruxolitinib
Defined as the apparent volume of distribution.
Measured: Up to Day 12
Pharmacokinetics Parameter: λz of plasma ruxolitinib
Defined as the terminal-phase disposition rate constant.
Measured: Up to Day 12
Pharmacokinetics Parameter: tmax of plasma povorcitinib
Defined as the time to maximum concentration.
Measured: Up to Day 12
Pharmacokinetics Parameter: t½ of plasma povorcitinib
Defined as the apparent terminal-phase disposition half-life.
Measured: Up to Day 12
Pharmacokinetics Parameter: CL/F of plasma povorcitinib
Defined as the apparent clearance.
Measured: Up to Day 12
Pharmacokinetics Parameter: Vz/F of plasma povorcitinib
Defined as the apparent volume of distribution.
Measured: Up to Day 12
Pharmacokinetics Parameter: λz of plasma povorcitinib
Defined as the terminal-phase disposition rate constant.
Measured: Up to Day 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2026
- Study start18 May 2026
- Primary completion8 Sep 2026
- Study completion5 Oct 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy ParticipantsStudies of the same condition, open and under way.
- More trials run by Incyte CorporationThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Incyte Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Incyte Medical Monitor, Study director, Incyte Corporation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07588139
- Sponsor's protocol ID
- INCB054707-113
- Status last verified
- Oct 2026
- First submitted
- 8 May 2026
- Last updated
- 9 Oct 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label, Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
- ClinicalTrials.gov ID
- NCT07588139
- Acronym / sponsor ID
- INCB054707-113
- Conditions
- Healthy Participants
- Keywords
- INCB054707
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- Incyte CorporationIndustry (pharma, biotech, devices)
- Study start
- 18 May 2026 (actual)
- Primary completion
- 8 Sep 2026 (actual)
- Study completion
- 5 Oct 2026 (actual)
- First posted
- 14 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the interstitial concentrations using the open-flow microperfusion device and plasma pharmacokinetics following multiple doses of povorcitinib or topical ruxolitinib cream in healthy adult participants.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Cohort 1: Ruxolitinib 1.5 % Cream | Experimental | Drug: RuxolitinibRuxolitinib cream applied topically twice daily. |
| Cohort 2: Povorcitinib | Experimental | Drug: PovorcitinibPovorcitinib will be administered at the protocol defined dose. |
| Cohort 3: Povorcitinib | Experimental | Drug: PovorcitinibPovorcitinib will be administered at the protocol defined dose. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Ability to comprehend and willingness to sign a written ICF for the study.
- Aged 18 to 65 years, inclusive, at the time of signing the ICF.
- Body mass index between 18.0 and 30.5 kg/m2, inclusive.
- No clinically significant findings on screening evaluations (clinical, laboratory, and ECG).
- Ability to swallow and retain oral medication.
Key exclusion criteria (37 listed)
- History of uncontrolled or unstable cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening.
- Participants with any history of an autoimmune disease diagnosis.
- History of cardiovascular, cerebrovascular, peripheral vascular, or thrombotic disease or uncontrolled hypertension.
- History or presence of an abnormal ECG.
- Presence or history of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn's disease or chronic pancreatitis).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PovorcitinibAlso: INCB054707Oral; Tablet | Drug | Cohort 2: Povorcitinib, Cohort 3: Povorcitinib |
| RuxolitinibRuxolitinib cream applied topically. | Drug | Cohort 1: Ruxolitinib 1.5 % Cream |
Primary outcome
Pharmacokinetics Parameter (PK): Cmax of dermal interstitial fluid (dISF) ruxolitinib
Time frame: Up to Day 12
Defined as the maximum observed plasma concentration.
Pharmacokinetics Parameter: AUClast of dISF ruxolitinib
Time frame: Up to Day 12
Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.
Pharmacokinetics Parameter: AUC∞ of dISF ruxolitinib
Time frame: Up to Day 12
Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.
Pharmacokinetics Parameter: Cmax of dISF povorcitinib
Time frame: Up to Day 12
Defined as the maximum observed plasma concentration.
Pharmacokinetics Parameter: AUClast of dISF povorcitinib
Time frame: Up to Day 12
Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.
Pharmacokinetics Parameter: AUC∞ of dISF povorcitinib
Time frame: Up to Day 12
Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.
Pharmacokinetics Parameter: Cmax of plasma ruxolitinib
Time frame: Up to Day 12
Defined as the maximum observed plasma concentration.
Pharmacokinetics Parameter: AUClast of plasma ruxolitinib
Time frame: Up to Day 12
Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.
Pharmacokinetics Parameter: AUC∞ of plasma ruxolitinib
Time frame: Up to Day 12
Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.
Pharmacokinetics Parameter: Cmax of plasma povorcitinib
Time frame: Up to Day 12
Defined as the maximum observed plasma concentration.
Pharmacokinetics Parameter: AUClast of plasma povorcitinib
Time frame: Up to Day 12
Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.
Pharmacokinetics Parameter: AUC∞ of plasma povorcitinib
Time frame: Up to Day 12
Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.
21 secondary outcomes
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Time frame: Up to Day 28
Pharmacokinetics Parameter: tmax of dISF ruxolitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: t½ of dISF ruxolitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: CL/F of dISF ruxolitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: Vz/F of dISF ruxolitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: λz of dISF ruxolitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: tmax of dISF povorcitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: t½ of dISF povorcitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: CL/F of dISF povorcitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: Vz/F of dISF povorcitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: λz of dISF povorcitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: tmax of plasma ruxolitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: t½ of plasma ruxolitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: CL/F of plasma ruxolitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: Vz/F of plasma ruxolitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: λz of plasma ruxolitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: tmax of plasma povorcitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: t½ of plasma povorcitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: CL/F of plasma povorcitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: Vz/F of plasma povorcitinib
Time frame: Up to Day 12
Pharmacokinetics Parameter: λz of plasma povorcitinib
Time frame: Up to Day 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2026.
- A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult ParticipantsLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Healthy Participants
Active, not recruitingPhase 1/2
Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions
Healthy Volunteer, Hypersensitivity Reactions
Active, not recruitingPhase 1/2
Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
Vasomotor Symptoms Associated With Menopause, Healthy Volunteers
RecruitingPhase 1
A Study in Healthy Men to Test How Well Different Doses of BI 3776528 Are Tolerated
Healthy
Enrolling by invitationObservational study
Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Primary Immunodeficiency, DOCK8
Not yet recruiting
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Healthy Volunteer, Malaria
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Incyte Medical Monitor study director
Incyte Corporation
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Povorcitinib and Ruxolitinib in people with Healthy Participants, run by Incyte Corporation at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 37 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pharmacokinetics Parameter (PK): Cmax of dermal interstitial fluid (dISF) ruxolitinib (time frame: Up to Day 12). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026.